INTRODUCTION
Chimeric antigen receptors (CARs) that redirect the specificity of autologous T cells against lymphoid malignancies have produced striking clinical results. [1] [2] [3] [4] [5] [6] Nonetheless, CAR-modified T cells have a number of limitations. The generation of an autologous product for each individual patient is logistically cumbersome and restrictive for widespread clinical use. The manufacturing of CAR-T cells often takes several weeks, making it impractical for patients with rapidly advancing disease. Furthermore, it is not always possible to generate clinically relevant doses of CAR-T cells from heavily pre-treated, often lymphopenic patients. A previously collected allogeneic product could overcome these limitations; however, allogeneic T cells (even if human leukocyte antigen (HLA)-matched) carry a risk of graft-versus-host disease, 7 mediated through their native αβ T-cell receptor.
Natural killer (NK) cells provide an attractive alternative to T cells for CAR engineering. NK cells do not cause graft-versus-host disease, 8, 9 and thus open opportunities to produce an off-theshelf product for immediate clinical use. Moreover, as engineered NK cells should also retain their full array of native receptors, they have the potential to exert cytotoxicity 10 through mechanisms other than that dictated by the specificity of the CAR, which in principle could reduce the risk of relapse mediated by loss of CARtargeted antigen, as reported for CAR-T-cell therapy. 11 Functional NK cells can be derived from several sources. 9, 12, 13 Autologous NK cells can be reproducibly generated in vitro, but have limited activity against autologous tumors, 14,15 which may not be overcome by CAR engineering. Cord blood (CB) is a readily available source of allogeneic NK cells with clear advantages. CB is available as an off-the-shelf frozen product, an advantage that has been bolstered by methods to generate large numbers of highly functional NK cells from frozen CB units ex vivo. 16 The generation of CAR-transduced NK cells from frozen CB units stored in large global CB bank inventories holds promise for widespread scalability that cannot be replicated with individual adult donors who require screening and leukapheresis. However, a major disadvantage of NK cells is their lack of persistence after adoptive transfer in the absence of cytokine support. 17 Finally, CARengineered NK cells may also exert potentially serious toxicity, such as cytokine release syndrome or off-tumor/on-target toxicity, as reported with CAR-T cells.
investigated whether these genetic modifications would enable CB-NK cells to persist in sufficient numbers to effectively kill B-cell malignancies.
MATERIALS AND METHODS

Cell lines
K562-based feeder cells expressing membrane-bound IL-21 and CD137-ligand (Clone 9.mbIL21) 16 were generously provided by Laurence Cooper, MD Anderson Cancer Center (MDACC). Clone 9.mbIL21 cells co-express CD64/FcγRI, CD86/B7-2, CD137L/4-1BBL, truncated CD19 and membranebound IL-21 was recently reported to promote peripheral blood and CB-NK cell expansion. 16, 22 Raji (Burkitt lymphoma cell line) and K562 (erythroleukemia cell line) were purchased from American Type Culture Collection (Manassa, VA, USA).
Patient details
Primary chronic lymphocytic leukemia (CLL) cells from six patients were used for in vitro studies of NK-CAR cytotoxicity. Patient characteristics are summarized in Supplementary Table 1 .
Plasmid construction and retrovirus production
The retroviral vectors encoding iC9.CAR19.CD28-zeta-2A-IL-15 and firefly luciferase have been described. 19, 23 Transient retroviral supernatants were produced as previously described. 23 Generation of CAR-modified NK cells CB units for research were provided by the MDACC CB Bank and peripheral blood mononuclear cells were collected from CLL patients following informed consent, under the institutional review board-approved protocols. CB and peripheral blood mononuclear cells were isolated by a density-gradient technique (Ficoll-Histopaque; Sigma, St Louis, MO, USA). CD56+ NK cells, purified with an NK isolation kit (Miltenyi Biotec, Inc., San Diego, CA, USA), were stimulated with irradiated (100 Gy) Clone 9 (2:1 feeder cell:NK ratio) and recombinant human IL-2 (Proleukin, 200 U/ml; Chiron, Emeryville, CA, USA) in complete serum-free stem cell growth medium) (CellGenix GmbH, Freiburg, Germany) on day 0. Activated NK cells were transduced with retroviral supernatants on day +4 in human fibronectin-coated plates (Clontech Laboratories, Inc., Mountain View, CA, USA). Five days later (day +9), NK cells were stimulated again with irradiated Clone 9 and IL-2. On day +14, CAR-transduced NK cells were collected for use.
CAR expression and immunophenotype of transduced cells
Transduced CB-NK cells were stained with Alexa-Fluor647 affinity-purified F (ab') 2 
Intracellular cytokine production
On day 14 of culture, control ex vivo-expanded non-transduced (NT) and CAR-transduced CB-NK cells (0.25 × 10 6 cells/well) were cocultured for 5 h in 96-well plates with purified CLL cells, Raji cells or K562 targets (positive control) at an effector:tumor cell ratio (E:T) of 5:1. CD107a degranulation and intracellular cytokine production were measured as previously described 14 (see Supplementary Material for assay details).
NK cell proliferation and cytotoxicity assays
To evaluate for autonomous NK cell growth, we maintained control ex vivoexpanded NT and iC9/CAR.19/IL-15 + NK cells in serum-free stem cell growth medium without stimulation or addition of exogenous cytokines. Cells were cultured for 42 days and counted using trypan blue exclusion every 3 days.
To assess cytotoxicity, CAR-transduced and ex vivo-expanded NT NK cells were cocultured with 51 Cr-labeled CLL, Raji and K562 targets (positive control) at multiple E:T ratios; cytotoxicity was measured by 51 Cr release as previously described, 14 the findings are reported as specific lysis relative to K562 targets. 24 For HLA-blocking experiments, the anti-HLA-ABC clone W6/32 (Biolegend, San Diego, CA, USA) was used.
Confocal microscopy and measurement of microtubule-organizing center polarization
Conjugates were imaged by sequential scanning with a Leica TCS SP8 (Buffalo Grove, IL, USA) laser scanning confocal microscope as previously described. 25 
Pathologic analysis
Mice were killed and necropsied 10 months after the first treatment, at the age of 13 months. Blood samples were collected immediately after euthanasia and analyzed with Advia 120 (Malvern, PA, USA). Formalin-fixed tissues were embedded in paraffin blocks, cut into 4 μm-thick sections, hematoxyin and eosin-stained and examined microscopically by a trained pathologist.
Statistical analysis
Student's t-test was used to compare quantitative differences (mean ± s.d.) between samples; P-values were two-sided and Po0.05 was considered significant. For all bioluminescence experiments, intensity signals were summarized as means ± s.d. at baseline and at multiple subsequent time points for each group of mice. 16 Probabilities of survival were calculated using the Kaplan-Meier method. Figure 1A) . Table 1 summarizes data on fold expansion and absolute CAR-NK counts from five different CB units. After 14 days of culture, the median NK cell expansion was 2222-fold (range 564-7370).
We studied the stability of CAR expression over time by culturing CAR-transduced CB-NK cells from six different CB units for a total of 7 weeks. CAR expression remained stable over this interval, as determined by flow cytometry every 10-14 days. To confirm that the enhanced cytotoxic activity against CD19 targets by CAR-CB-NK cells is derived from the iC9/CAR.19/IL-15-expressing fraction of the product, we measured CD107a degranulation and interferon-γ and tumor necrosis factor-α (TNF-α) response to Raji and CLL targets (n = 8). As shown in Figure 1c , the CAR-positive NK cell fraction was the main source of interferon-γ, tumor necrosis factor-α and CD107a in response to CD19+ targets, compared to the CAR-negative fraction, while the CAR-positive and CAR-negative fractions showed similar effector function against K562 cells.
CB-derived iC9/CAR.19/IL-15-transduced NK cells have superior cytotoxicity against primary CLL targets, compared to CLL patientderived NK cells transduced with the same vector We generated both NT and iC9/CAR.19/IL-15-transduced NK cells from 2 CLL patients using the methodology described above and tested their ability to lyse autologous CLL cells in three independent experiments. We also compared their cytotoxicity with those of CB-derived iC9/CAR.19/IL-15-transduced and NT NK cells. Expanded NT NK cells from CLL patients and CB were equally poorly cytotoxic against CLL targets (Supplementary Figure 2A) . However, whereas CAR-transduced CB-NK cells could efficiently kill CLL cells, expression of the same vector by NK cells from patients only modestly increased their cytotoxicity against autologous CLL targets, suggesting that transduced NK cells from CLL patients will be less-effective immunotherapy than healthy CAR-transduced CB cells. To investigate whether an inhibitory effect of killer immunoglobulin receptor/self-HLA interaction could have impaired the cytotoxicity of patient-derived CAR-NK cells against autologous CLL cells, we repeated the experiments in the presence or absence of HLA class-I blocking (Supplementary Figure 2B) . This intervention only partially improved the cytotoxicity of patient-derived CAR-transduced NK cells against autologous targets. CLL cells express high levels of HLA-E (Supplementary Figure 2C) , the ligand for the inhibitory receptor NKG2 A. Thus, to determine whether an inhibitory effect of NKG2A/HLA-E interaction could influence patient-derived CAR-NK killing of autologous CLL cells or CB CAR-NK mediated killing of CLL targets, we repeated the experiments in the presence or absence of an NKG2A-blocking antibody (clone Z199, Beckman Coulter, Indianapolis, IN, USA). As shown in Supplementary Figures 2D and E, NKG2A blocking significantly improved the ability of both NT NK and CAR.19-transduced CLL-NK and CB-NK cells to recognize and kill primary CLL cells, without significantly influencing their cytotoxicity against K562 cells (Supplementary Figure 2D) . Taken together, these data suggest that multiple mechanisms likely contribute to the relative inability of CARtransduced patient-derived NK cells to kill autologous targets and that strategies to block NKG2A may further improve the efficacy of this approach. Increased polarization of the microtubule-organizing center (MTOC) is an essential step in the final stages of NK cell-mediated cytotoxicity and exocytosis of lytic granules at the IS. 27 Thus, we used confocal microscopy to assess the MTOC polarization of ex vivo-expanded NT CB-NK cells, iC9/CAR.19/IL-15 + CB-NK, CLL patient-derived iC9/CAR.19/IL-15 + NK cells and CAR.19-transduced CB-NK (lacking IL-15) in experiments with CLL targets. MTOC polarization was quantified by measuring the distance between the pericentrin-defined MTOC to the IS for at least 15 conjugates, including all four groups of NK cells and CLL targets. MTOC polarization against K562 targets was used as control as NK cells form a 'natural' synapse with K562 targets through multiple activating receptors on their surface. As shown in Figure 2c and Supplementary Figure 3 Figure 4) . + CB-NK cells expanded for 2 weeks showed no signs of exhaustion, such as downregulation of eomesodermin and T-bet, 28 or upregulation of KLRG1, and in fact exhibited a phenotype similar to that of ex vivoexpanded NT NK cells. Moreover, in contrast to a previous report in murine NK cells that sustained stimulation with IL-15/IL-15 R-α complexes induces dysfunction, 29 human iC9/CAR.19/IL-15-transduced CB-NK cells proliferated as efficiently as NT CB-NK cells in culture and followed a similar kinetic of in vitro expansion (Figure 3c) . (Figures 4g and h; Supplementary Figures 6A and B) ; however, it was associated with significant toxicity, and early mortality and treatment-related mortality (defined as death before day 21) when compared with CAR19/IL-15 NK cells (P = 0.038).
We next asked whether increasing the dose of CB-NK cells could enhance antitumor activity by administering two intravenous infusions ( Nine mice treated with CB-NK cells transduced with iC9/CAR.19/ IL-15 (n = 5) or CAR.CD19 (lacking IL-15; n = 4) were followed for at least 10 months and then killed. The hematologic parameters were within normal ranges (Supplementary Table 2) , with no evidence of lymphocytic leukemia in either treatment group (Figure 5b ).
iC9/CAR.19/IL-15
+ CB-NK cells are eliminated by activation of the suicide gene with a small-molecule dimerizer To counteract excessive toxicity mediated by the release of inflammatory cytokines by transduced CB-NK cells, we incorporated a suicide gene (iC9) into our construct. 21 The addition of as little as 10 nM of the small-molecule dimerizer AP1903 to cultures of iC9/CAR.19/IL-15-transduced CB-NK cells induced apoptosis/ necrosis of transduced NK cells within 4 h but had no effect on the viability of NT CB-NK cells (Figures 6a and b) . The suicide gene was also effective in vivo. Mice engrafted with Raji tumor received iC9/ CAR.19/IL-15-transduced CB-NK cells. Mice were then either treated with the dimerizer or not (n = 5 mice per group) and were killed 3 days later. Administration of the small-molecule We chose CD19 as the target for our studies, as proof of principle, based on the striking clinical efficacy shown by CAR. CD19+ T cells against B-lineage cancers. [1] [2] [3] [4] [5] [6] The signaling domain of our construct contains CD28 and CD3ζ. CD3ζ is crucial for both T-and NK cell signaling and activation. 30, 31 While CD28 is well recognized as an important costimulatory molecule for T-cell activation, 32 its role in NK cell activation is less clear; however, human fetal NK cells and a number of NK cell lines express CD28 and can kill CD80/CD86-expressing tumor targets, supporting a role for CD28 in the activation of NK cells. [33] [34] [35] Further, CD28 ligation in NK cells enhances NK cell killing of its target by phosphorylating ERK2. 27 In our study, NK cells transduced with a CAR incorporating CD28 showed marked antitumor activity, both in vitro and in vivo, although other costimulatory domains, such as 4-1BB, 17 may improve results further. CAR-NK cells also exert cytotoxicity that is non-CAR.CD19-mediated, as demonstrated by the modest killing of tumor targets by NT NK cells. This could represent an advantage for NK cells over T cells in CAR-driven immunotherapy, as the intrinsic capacity of NK cells to recognize and target tumor cells remains intact, making disease escape through downregulation of the CAR target antigen less likely than it is with CAR-T cells. One could potentially exploit this property by selecting donors for NK-CAR production based on killer immunoglobulin receptor-ligand mismatch with the recipient, or haplotype B killer immunoglobulin receptor gene content, as shown in the setting of stem cell transplantation. 8, 13, [36] [37] [38] Using readily accessible CB units and GMP-compliant procedures for robust expansion, 19 it is feasible to generate multiple clinical doses of CAR-NK cells from a single CB unit (Table 1) .
Mature NK cells have a short lifespan with poor in vivo persistence both in humans and in mice, 39, 40 although recent data support the existence of a subset of long-lived memory NK cells in mice 41, 42 and adaptive/memory NK cells in humans. [43] [44] [45] [46] [47] In vivo persistence of effector cells are crucial for sustained clinical responses. 48 We therefore incorporated in our construct the gene encoding IL-15, a cytokine that drives NK cell expansion and persistence. 19, 20, 49 This modification led to ectopic production of IL-15, which was predominantly antigen-driven, and to more robust activation of NK cells with enhanced in vivo proliferation, persistence and antitumor activity than that seen with CAR.19-transduced NK cells lacking IL-15. Although the latter could mediate an antitumor response, the effect was only transient, further emphasizing the importance of in vivo persistence of CARexpressing NK cells for effective and durable antitumor immunity. We also examined whether exogenous administration of IL-15 could support the in vivo proliferation and antitumor activity of CAR19-transduced NK cells, thus, overcoming the requirement to include IL-15 in the construct. However, IL-15, even when administered at a low dose of 0.5 μg/mouse every 2-3 days, 26 was associated with significant toxicity when administered in combination with CAR.CD19-transduced CB-NK cells (but not NT NK cells), supporting our strategy to include IL-15 in the construct. It is conceivable that ectopic IL-15 production could lead to abnormal NK cell proliferation or leukemia transformation. 50 In the present study only picogram quantities of IL-15 were produced by our CAR-transduced CB-NK cells, without evidence of autonomous growth in vitro or leukemic transformation in vivo.
Severe toxicity, including on-target/off-tumor effects and cytokine release syndrome is a major clinical limitation of CAR-Tcell therapy. 51 These concerns may also be relevant to CAR-NK cells. Human NK cells predominantly produce interferon-γ, IL-3 and granulocyte-macrophage colony-stimulating factor, 50 which may result in a different pattern and kinetic of cytokine release syndrome. In our study infusion of a higher number of iC9/CAR.19/ IL-15-transduced CB-NK cells was associated with a systemic inflammatory response and toxic death in a number of mice. To counteract these potential toxicities, we equipped CAR-modified NK cells with an inducible suicide gene 21 and showed that pharmacologic activation of this molecule could rapidly and efficiently eliminate the gene-modified NK cells.
In conclusion, we have developed a novel approach to immunotherapy using engineered CB-derived NK cells. The iC9/ CAR.19/IL-15-transduced CB-NK cells are relatively easy to produce, show striking efficacy both in vitro and in vivo, and incorporate safety measures that are designed to limit toxicity. Clinical trials of these CAR-NK cells have begun at our center.
